Asbestos-related chest disease is a dubious disease in the field of infectious respiratory digestive and endocrine disorders. Clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis.
The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation. The platform can help to connect a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many infectious respiratory digestive endocrine disorders that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored during the treatment process, and timely adjusted according to the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of asbestos-related chest diseases. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.